Celanese Q3 Net Sales $2.6 Billion, Up 6% Year-on-Year

Celanese reported Q3 2026 net sales of $2.6B, up 6% YoY but down 7% QoQ. EPS was $0.68 GAAP and $1.65 adjusted. Operating income was $198M, adjusted EBITDA $367M. Engineering Materials sales fell 1% YoY, while Acetyl Chain sales rose 14% YoY. Operating cash flow was $538M, free cash flow $461M.

Original reporting
Published Nov 11, 2026, 12:13 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 11, 2026, 12:35 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$CE
Neutral
high confidence
Mentioned
$CE
Relevance
4/10
AlphAI data visualization · based on autonews.gasgoo.com
Decision brief

The 30-second read

$CENeutralLow
01

Why it matters

Recap provides no new data; traders gain little actionable insight.

02

Market read

Low relevance; primarily a summary of already-public earnings.

03

What to watch

Potential upside from medical and electronics demand not fully priced in.

Relevance 4/10Novelty 2/10Timing: none

Background

Celanese's Q3 2026 earnings were released on 2026-11-02; this article repeats those figures.

Company-level read

Ticker impact

$CENeutralHigh confidence
Context

Q3 2026 results recapped; net sales $2.6B, EPS $0.68, higher tax rate and goodwill impairment noted.

Expected impact

likely slight pressure as market prices in higher tax rate and lack of new growth drivers

Evidence & confidence

No fresh information beyond prior release; investors may view results as expected, limiting upside.

Market effects

Chemicals sector sees modest growth; no sector-wide catalyst.

U.S. market impact minimal.

Limited global relevance.

Counterpoint

If investors focus on segment strength in Acetyl Chain, stock could hold steadier than implied.

Key entities

  • Celanese

    Chemicals manufacturer, ticker CE.

Related articles

$CEMed

BMO raises Celanese stock price target to $58 on cost cuts

BMO Capital increased its price target for Celanese (NYSE:CE) to $58 from $56, citing cost-cutting and cash generation. The firm expects higher estimates for 2027-2028 due to growth in engineered materials, despite challenges in the acetyl chain business. Celanese reported Q3 2026 earnings of $1.65 per share, beating estimates, but revenue fell short. Other analysts have also raised price targets.

$CEMed

Celanese Corp (CE) Q3 2026 Earnings Call Highlights: 2027 Free Cash Flow Outlook

Celanese Corp (CE) reported Q3 2026 earnings, with CFO Chuck Kyrish highlighting $70M in cost savings this year and $30M-$40M expected in 2027. CEO Scott Richardson noted strong demand from AI data center build-outs driving growth in electronics. Q4 guidance includes a 6-7% volume decline in Engineered Materials and a $25M decline in acetyls. The company expects margin compression in Q4 due to methanol prices and other cost pressures.

$CEMedAI 8/10

Celanese Q3 Earnings Call Highlights

Celanese (NYSE: CE) expects restructuring costs to decrease by $30M-$40M in 2027 and additional cost savings of $30M-$40M in 2027. The company targets $150M in productivity improvements to offset inflation. Engineered Materials segment sees growth in electronics and healthcare, while automotive and nylon conditions remain mixed. Acetyl Chain faces margin compression due to outages and cost pressures.

$CEMed

Celanese (CE) Q3 2026 Earnings Call Transcript

Celanese (CE) reported Q3 2026 earnings, highlighting $100M in cost savings for 2027 and $700M-$800M in free cash flow. The company expects growth in electronics and healthcare segments to continue into 2027, while addressing potential capacity needs in downstream derivatives. Management discussed market dynamics in Asia and the impact of tariff changes on VAM. According to the company, they remain focused on productivity and targeted investments.

$CEMedAI 8/10

Celanese Q3 2026 slides: specialty focus drives margin gains

Celanese (NYSE:CE) reported Q3 2026 earnings with revenue of $2.56B, missing estimates, but EPS of $1.65 beat expectations. The company highlighted strong free cash flow of $461M and raised full-year guidance to $750M-$800M. Shares rose 3.86% to $49.79. Celanese is shifting focus to high-margin specialty applications in medical and electronics, driving margin expansion.

$CEHighAI 8/10

Why is Celanese stock rallying today?

Celanese (CE) stock rose 4.3% in pre-market trading after reporting Q3 adjusted EPS of $1.65, beating estimates. Revenue grew 6% YoY to $2.56B, missing slightly. The company raised its full-year 2026 EPS guidance to $6.00–$6.25. Analysts Mizuho and BofA increased price targets. The S&P 500 and NASDAQ showed mild gains.